PDCD1 and mesothelioma: In the context of combined approaches involving angiogenesis-targeting agents and ICIs, it is worth mentioning a single-arm, phase II study in which the anti-PD-1 antibody Pembrolizumab has been evaluated in combination with the antiangiogenic multikinase inhibitor Lenvatinib in a small cohort of patients with mesothelioma who progressed after standard chemotherapy [73].